Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jul;82(969):417-24.
doi: 10.1136/pgmj.2005.038455.

Treatment of inflammatory myopathies

Affiliations
Review

Treatment of inflammatory myopathies

A C Cordeiro et al. Postgrad Med J. 2006 Jul.

Abstract

Idiopathic inflammatory myopathies, notably polymyositis and dermatomyositis are comparatively uncommon diseases and few randomised, double blind placebo controlled trials have been done. Final validation of measures to assess outcome and response to treatment is awaited. Corticosteroids are an effective initial treatment, although rarely tested in randomised controlled trials. Unfortunately, not all patients respond to them and many develop undesirable side effects. There is thus a need for second line agents notably immunosuppressives or intravenous immunoglobulin. There are no defined guidelines or best treatment protocols agreed internationally and so the medical approach must be individualised, based on the severity of clinical presentation, disease duration, presence of extramuscular features, and prior therapy and contraindications to particular agents. There is still a significant percentage of non-responders (around 25%) and clinical relapses. Novel therapeutic approaches are now directed towards cytokine modulation and the use of monoclonal antibodies targeting B and T cells.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none declared.

Similar articles

Cited by

References

    1. Isenberg D A, Ramsey‐Goldman R. Assessing patients with lupus: towards a drug responder index. Rheumatology 1999381045–1049. - PubMed
    1. Choy E H S, Isenberg D A. Treatment of dermatomyositis and polymyositis. Rheumatology 2002417–13. - PubMed
    1. Dalakas M. Polymyositis and dermatomyositis. Lancet 2003362971–982. - PubMed
    1. Oddis C. Idiopathic inflammatory myopathies: a treatment update. Curr Rheumatol Rep 20035431–436. - PubMed
    1. Mastaglia F, Garlepp M, Phillips B.et al Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 200327407–425. - PubMed

MeSH terms

Substances